Articles from ICON plc

ICON plc, (NASDAQICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2025. For the full year 2025, revenue is expected to be in the range of $8,050 - $8,650 million, representing growth of approximately 1% at the midpoint and adjusted earnings per share* is expected to be in the range of $13.00 - $15.00, which is flat over the expected full year 2024 adjusted earnings per share guidance midpoint.

ICON plc, (NASDAQICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders. The findings indicate that, despite recent successes in developing disease modifying treatments for Alzheimer's, persistent challenges that remain in neurodegenerative clinical trials can be mitigated by underutilised trial methodologies.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 3.45pm PST.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured with numerous awards in the second half of 2024.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Barry Balfe as Chief Operating Officer (COO).

ICON plc, (NASDAQICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced results from a recent global survey of 101 biotech and pharma professionals across Europe and North America to understand the trajectory of AI and digital innovation adoption within clinical research.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc and Mr. Nigel Clerkin, CFO of ICON plc will present at the Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 8:00am GMT.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the third quarter ended September 30, 2024.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the third quarter 2024 after the market closes on Wednesday, October 23, 2024. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, October 24, 2024 at 8:00am ET.

ICON plc, (NASDAQICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced results from a recent survey of over 100 professionals engaged in oncology drug development to understand the current state of emerging oncology treatment development, including the associated clinical trial dynamics. Respondents acknowledged that much focus has been accorded to emerging oncology treatments; however, as of yet, there are varied views on the degree to which these precision approaches will improve patient outcomes.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Baird 2024 Global Healthcare Conference on Tuesday, September 10, 2024 at 3:45 pm ET.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Nigel Clerkin as its new Chief Financial Officer (CFO).

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the second quarter ended June 30, 2024.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 23, 2024 were duly passed by shareholders. ICON also confirmed that following the conclusion of the company's AGM, Joan Garahy retired as a non-executive director and announced that Anne Whitaker was appointed as a non-executive director.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2024 with a number of leading business and industry awards recognising the company’s leadership position in the clinical research industry, in addition to its efforts in inclusion, sustainability and as an employer of choice.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the second quarter 2024 after the market closes on Wednesday, July 24, 2024. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, July 25, 2024 at 8:00am ET.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 1:30pm ET.

ICON plc, (NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, will host its 2024 Investor Day today in New York City. The event will feature presentations from ICON’s executive team and provide further details on the strategic initiatives that will drive the near and long-term outlook for the company. The event will begin at 10 am EST and can be joined via webcast here.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that it will hold an Investor Day which will take place on Thursday, May 30, 2024 in New York City, starting at 10am ET. The event will include presentations from members of ICON’s executive team, and access to a live webcast will be made available in on the Investor section of our website. It is expected that the presentations, followed by a question and answer session, will conclude at approximately 1pm ET.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today releases its ICON Cares 2023 Report. This outlines how the company is delivering on its ESG, diversity, inclusion and belonging, and CSR goals, as delivered through its ICON Cares program.

ICON plc (NASDAQICLR) (“ICON”), a world-leading healthcare intelligence and clinical research organization, today announced the pricing of a USD 2 billion SEC-registered bond offering, consisting of $750,000,000 5.809% Senior Secured Notes due 2027, $750,000,000 5.849% Senior Secured Notes due 2029 and $500,000,000 6.000% Senior Secured Notes due 2034 (collectively, the “Notes”).

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the first quarter ended March 31, 2024.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today announced that Chief Financial Officer, Brendan Brennan, will leave his role at ICON in quarter four this year for a new opportunity outside of the CRO industry. Brendan has held the role since 2012 and will remain with the company in his current role as CFO to ensure a smooth transition to a newly appointed Chief Financial Officer. ICON has commenced a search to identify the next CFO.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the first quarter 2024 after the market closes on Wednesday, April 24, 2024. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, April 25, 2024 at 8:00am ET.

ICON plc, (NASDAQICLR) a world-leading clinical research organization powered by healthcare intelligence, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the TD Cowen 44th Annual Healthcare Conference on Tuesday, March 5, 2024 at 11:10 am ET and Dr. Steve Cutler, CEO of ICON plc, will present at the Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12, 2024, at 2:05 pm ET.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the fourth quarter and year ended December 31, 2023.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the fourth quarter and full year 2023 results after the market closes on Wednesday, February 21, 2024. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, February 22, 2024 at 8:00am ET.

ICON plc, (NASDAQICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced results from a recent industry survey of over 100 professionals engaged in obesity-related clinical research to measure industry opinions on trends within this therapeutic area. The majority of respondents believe the future of obesity therapies lies in trials that are designed to measure more than one outcome. There is much overlap between obesity and co-morbidities such as diabetes, steatosis (fatty liver), and cardiovascular disease, and in line with this, most respondents (64%) felt combination therapies would be the primary focus of future research. Furthermore, half of respondents are employing multi-indication studies in their current obesity-related clinical studies.

ICON plc, (NASDAQICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2024. For the full year 2024, revenue is expected to be in the range of $8,400 - $8,800 million, representing growth of 3.2% – 8.1%, and adjusted earnings per share1 is expected to be in the range of $14.50 - $15.30, representing growth of 13.5% – 19.8%, over Full Year 2023 revenue and adjusted earnings per share guidance midpoints, respectively.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today launched its “Optimising biotech funding” whitepaper. This provides an overview of the current state of play for biotech companies and the research and development (R&D) strategies they can adopt to attract and best utilise investment funding.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organization, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 5:15pm PST/8.15pm EST.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation (CRO), finishes the second half of 2023 with positive recognition as a top-rated employer and leader in clinical trial innovation.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today announced that Moody's Investors Service ("Moody's") upgraded all of ICON plc’s instrument ratings to Baa3 with a stable outlook. This reflects the stronger credit profile of the ICON Group, which Moody’s now views as comparable in aggregate to Baa3 peers. The Baa3 rating of all the instruments reflects Moody’s view that the ICON Group has reached an investment grade financial profile.

ICON plc, (NASDAQICLR) a world-leading clinical research organization powered by healthcare intelligence, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the Jefferies London Healthcare Conference on Tuesday, November 14, 2023 at 2:00pm GMT. Mr. Brendan Brennan will also present at the Evercore HealthCONx Conference on Wednesday, November 29, 2023, at 12:30pm ET.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the third quarter ended September 30, 2023.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today announced that S&P Global Ratings (S&P) upgraded ICON to an investment grade credit rating of BBB- with a stable outlook, based on operating performance and deleveraging.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the third quarter 2023 after the market closes on Wednesday, October 25, 2023. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, October 26, 2023 at 8:00am ET.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today announces the release of its next generation Clinical Trial Tokenisation solution. The combination of ICON’s proprietary tokenisation engine, access to real-world data and advanced clinical analytics expertise, now delivered through a cohesive and seamless operational model, provides valuable, long-term insights on drug safety and efficacy, throughout the product development lifecycle.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today announces that it is partnering with the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to execute a clinical trial to evaluate the effectiveness of next generation COVID-19 vaccine candidates.

ICON plc, (NASDAQICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Baird Global Healthcare Conference on Wednesday, September 13, 2023 at 10:15 am ET.

ICON plc (NASDAQICLR) (“ICON”), a world-leading healthcare intelligence and clinical research organisation, today announced that all resolutions at the Annual General Meeting of the Company (AGM) held on July 25, 2023 (which resolutions had all been recommended by the Board) were all duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 12, 2023 and are available on the ICON plc website.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the second quarter ended June 30, 2023.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, has received positive recognition from leading business and industry organisations as a leading CRO of choice and a top-rated employer in the first half of 2023.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the second quarter 2023 after the market closes on Wednesday, July 26, 2023. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, July 27, 2023 at 8:00am ET.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today announced the latest release of its Digital Platform. The platform supports seamless integration of ICON patient, site and sponsor services with the delivery of harmonised data and can be customised for any study design, from traditional to fully decentralised, and for any therapeutic area.

ICON plc, (NASDAQICLR), is set to join the broad-market Russell 3000® Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens today, Monday, June 26.

ICON plc, (NASDAQICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the William Blair 43rd Annual Growth Stock Conference on Tuesday, June 6, 2023 at 2:40pm CT and Mr. Brendan Brennan, CFO of ICON plc, will attend the UBS Healthcare Services Conference on Wednesday, June 28, 2023.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today releases its ICON Cares 2022 Environmental, Social and Governance (ESG) Report. The company’s ICON Cares initiative incorporates its ESG, Diversity, Inclusion and Belonging and Corporate Social Responsibility initiatives under one program.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the first quarter ended March 31, 2023.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the first quarter 2023 after the market closes on Wednesday, April 26, 2023. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, April 27, 2023 at 8:00am ET.

ICON plc, (NASDAQICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the 2023 Citi Healthcare Conference on Thursday, March 2, 2023 at 2pm ET. Dr. Steve Cutler, CEO of ICON plc, will present at the Barclays Global Healthcare Conference on Wednesday, March 15, 2023. The presentation will be webcast live from 1.35pm ET.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the fourth quarter and year ended December 31, 2022.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organisation, today announced that it will release its financial results for the fourth quarter 2022 after the market closes on Wednesday, February 22, 2023. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, February 23, 2023 at 8:00am ET.

ICON plc, (NASDAQICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2023. For the full year 2023, revenue is expected to be in the range of $7,940 - $8,340 million, representing growth of 3.3% – 6.8%, and adjusted earnings per share1 is expected to be in the range of $12.40 – $13.05, representing growth of 6.4% – 10.1%, over Full Year 2022 revenue and adjusted earnings per share guidance, respectively.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 5:15pm PST/ 8.15pm EST.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, has been recognised with a number of coveted business and industry awards over the second half of 2022 for delivering clinical research services, alongside specialist collaborations on data, analytics and digital healthcare.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the 2022 Evercore ISI HealthCONx Conference on Wednesday, November 30, 2022. The presentation will be webcast live from 08:00am EST.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the third quarter ended September 30, 2022.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today announces that it has been selected by the US Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the Department of Health and Human Services (HHS), to execute an anthrax vaccine clinical trial.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organisation, today announced that it will release its financial results for the third quarter 2022 after the market closes on Wednesday, November 2, 2022. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, November 3, 2022 at 8:00am ET.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today releases its 2021 Environmental, Social and Governance (ESG) Report.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022. The presentation will be webcast live from 10:25am EDT.

ICON plc (NASDAQICLR) ) (“ICON”), a world-leading healthcare intelligence and clinical research organisation, today announced that all resolutions at the Annual General Meeting of the Company (AGM) held on July 26, 2022 (which resolutions had all been recommended by the Board) were all duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 17, 2022 and are available on the ICON plc website.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the second quarter ended June 30, 2022.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organisation, today announced that it will release its financial results for the second quarter 2022 after the market closes on Wednesday, July 27, 2022. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, July 28, 2022 at 8:00am ET.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022, at 7.00am ET. It was also announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Jefferies Healthcare Conference on Thursday, June 9, 2022. The presentation will be webcast live from 2.00pm ET.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022, at 5:20pm PT.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organisation, today reported its financial results for the first quarter ended March 31, 2022.

ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organisation, today reported its financial results for the fourth quarter and full year ended December 31, 2021.

ICON plc, (NASDAQICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the 2022 Citi Healthcare Conference on Thursday, February 24, 2022 at 11:45am ET.

ICON plc, (NASDAQICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 40th Annual JP Morgan Healthcare Conference on Wednesday, January 12, 2022 at 07.30am ET.

ICON plc, (NASDAQICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device, and government organisations, is proud to announce it was named the “Best Contract Research Organisation” of 2021 during the 17th Annual Scrip Awards ceremony on 2 December.

ICON plc (NASDAQICLR) announced today the release of its 2020 Environmental, Social and Governance (ESG) Report. With the completion of ICON’s acquisition of PRA Health Sciences, the report presents a unified overview of the ESG advancements of both legacy organisations during 2020 and sets out the commitments, policies, and outlook for the combined company.

ICON plc, (NASDAQICLR) a global provider of drug development and commercialisation services to pharmaceutical, biotechnology, medical device, and government organisations, today announced that its Accellacare Site Network has expanded in reach and capabilities through new partnerships with six research sites across four countries.

ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at: